$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
What is the effect of nivolumab on lung cancer
2025-10-19 11:44:20
Check Details
Focus on NSCLC, AstraZeneca’s ADC new drug submits clinical application in China
2025-10-19 11:44:20
Check Details
Contraindications for taking nivolumab
2025-10-19 11:44:20
Check Details
How often should you lose nivolumab
2025-10-19 11:44:20
Check Details
Conditional activation blocks VISTA to inhibit solid tumors, and the US FDA approves the new drug research application of SNS-101
2025-10-19 11:44:20
Check Details
Acting on the tumor microenvironment, Parthenon announced that the self-developed drug PRTH-101 has completed the first patient administration in the phase I clinical trial
2025-10-19 11:44:20
Check Details
Innovent Biologics/Eli Lilly's RET inhibitor "Seputinib" is officially commercialized in China_Canghule
2025-10-19 11:44:20
Check Details
Express delivery! Novartis c-Met inhibitor "capmatinib" applies for marketing in China
2025-10-19 11:44:20
Check Details
The efficacy of nivolumab in treating gastric cancer: is it an immune drug or a targeted drug?
2025-10-19 11:44:20
Check Details
What is the effect of nivolumab combined with chemotherapy? What drug should be used with chemotherapy?
2025-10-19 11:44:20
Check Details
Is gefitinib a targeted drug and is it effective?
2025-10-19 11:44:20
Check Details
What are the indications and pharmacological effects of erlotinib?
2025-10-19 11:44:20
Check Details
1
2
...
10193
10194
10195
10196
10197
10198
10199
...
10234
10235
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Lyrfigtu (lirafugratinib) for Pretreated FGFR2 Cholangiocarcinoma: 70mg Daily, REFOCUS Efficacy, Ocular and Phosphate Monitoring
2
Pemigatinib for FGFR2 Cholangiocarcinoma and FGFR1 Hematologic Use: First-Line Data, 21-Day Dosing, Phosphate and Ocular Management
3
Belumosudil for cGVHD: 200mg with Food, Pregnancy Contraception, Liver Monitoring, Drug Interactions
4
Elagolix GnRH Antagonist for Endometriosis Pain: Mechanism, Dosing, Bone and Mood Safety
5
Diazoxide Oral Suspension Inadequate Response: Glucose-Based Titration, Stop at 2–3 Weeks, Re-evaluate Hypoglycemia Cause
6
Ambrisentan Adjunct for IgA Nephropathy Proteinuria: ETA Mechanism, Real-World Evidence, Safety Monitoring
7
Dabrafenib (Tafinlar) Complete Guide: Indications, Dosing, Combination Therapy and Safety
8
Binimetinib plus Encorafenib for BRAF‑Mutant Melanoma
9
Lemborexant for Insomnia: Dual Orexin 5/10mg, 7-Hour Bedtime, 7–10-Day Review and Safety
10
Fayuvi (rebisufligene etisparvovec-hopf) for MPS IIIA: AAV9 Single Infusion, Weight-Based Dose, Steroids, Liver/Platelet Monitoring
11
Trelagliptin Once-Weekly DPP-4 for Type 2 Diabetes: Dosing, Renal Adjustment, Discontinuation
12
Orforglipron (Foundayo) vs Metformin: Oral GLP-1 Weight Loss and T2D Use